Rakhmatullov F K, Klimova S V, Rudakova L E, Pchelinsteva S A, Rakhmatullov A F, Khodakova A I
Klin Med (Mosk). 2012;90(10):31-4.
The study included 58 patients with CHD and paroxysmal atrial fibrillation divided into 2 groups depending on thyroid hormone and thyrotropin levels. Group 1 was comprised of 24 patients with subclinical hypothyroidism, group 2 of 18 ones with subclinical hyperthyroidism. Control group consisted of l6 patients with CHD, paroxysmal atrial fibrillation and normal thvroid function. It was shown that patients with CHD, paroxysmal atrial fibrillation and subclinical thyrotoxicosis had T3 and T4 levels 92.6 and 72.5% higher than those with subclinical hypothyroidism. Subclinical thyroid dysfunction was shown to influence hemodynamic isoelectric parameters of the heart. Therapy of paroxysmal atrial fibrillation in CHD patients with subclinical hypothyroidism or hyperthyroidism with simultaneous correction of thyroid function increases the efficacy of anti-arrhythmic therapy up to 50 and 45.9% respectively.
该研究纳入了58例冠心病合并阵发性心房颤动患者,根据甲状腺激素和促甲状腺激素水平将其分为2组。第1组由24例亚临床甲状腺功能减退患者组成,第2组由18例亚临床甲状腺功能亢进患者组成。对照组由16例冠心病合并阵发性心房颤动且甲状腺功能正常的患者组成。结果显示,冠心病合并阵发性心房颤动及亚临床甲状腺毒症患者的T3和T4水平分别比亚临床甲状腺功能减退患者高92.6%和72.5%。亚临床甲状腺功能障碍被证明会影响心脏的血流动力学等电参数。对亚临床甲状腺功能减退或亢进的冠心病阵发性心房颤动患者进行治疗并同时纠正甲状腺功能,可使抗心律失常治疗的疗效分别提高至50%和45.9%。